|
|
|
|
|||||
|
|
|
New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves
| 7 hours | |
| Sep-25 | |
| Sep-25 | |
| Sep-20 | |
| Sep-20 | |
| Sep-16 | |
| Sep-09 | |
| Sep-02 | |
| Aug-28 | |
| Aug-06 | |
| Jul-30 | |
| Jun-26 | |
| Jun-25 | |
| Jun-23 | |
| Jun-16 | |
| Jun-03 | |
| Jun-03 | |
| May-30 | |
| May-30 |
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
TEVA
GlobeNewswire
|
| May-29 | |
| May-27 | |
| May-27 | |
| May-27 | |
| May-22 | |
| May-20 | |
| May-20 | |
| May-19 | |
| May-19 | |
| May-15 | |
| May-12 | |
| May-07 | |
| May-07 | |
| May-05 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite